Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
复制标题
DOI：
10.1186/s13054-020-03020-3
复制
发表时间：
2020-06-11
期刊：
影响因子：
15.1
通讯作者：
Blandizzi, Corrado
中科院分区：
文献类型：
--
作者：
Convertino, Irma;Tuccori, Marco;Blandizzi, Corrado
Sars-CoV-2并发症包括肺炎和急性呼吸窘迫综合征（ARDS），需要入住重症监护病房。这些疾病迅速使卫生保健系统不堪重负，对护理质量产生不利影响，并增加了死亡率。世界各地都实施了社会隔离战略，目的是减轻医院的压力。在治疗策略中，使用免疫调节药物来改善预后似乎是有希望的。特别是，由于肺炎和ARDS与细胞因子风暴有关，目前正在研究抗il -6、抗tnf和JAK抑制剂等治疗类药物。在这篇文章中，我们讨论了最有前途的药理学方法的潜在优势。
Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.